Desk›Healthcare› Gennex Laboratories Ltd
Gennex Laboratories Ltd
BSE 531739 · NSE GENNEX · ISIN INE509C01026 · Group X · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹12.96
+6.93%
BSE close, 28 August 2026
₹294.77 cr
22.7 cr shares · Micro cap
₹225.12 cr
as published
19.6× · 1.76×
EPS ₹0.66 · BV ₹7.36
119.86 / 16.13
₹ cr, as filed
15
4 selected · 27%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -24.9% |
|---|---|
| Against 52-week low | +83.8% |
| Day change | +6.93% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹0.66 |
|---|---|
| Price / earnings | 19.64× |
| Price / book | 1.76× |
| Book value — derived, price ÷ P/B | ₹7.36 |
| Return on equity | 8.90% |
| Operating margin | 14.28% |
| Net margin | 11.40% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 8.96%
- ROE as published
- 8.90%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 34.68 | 3.96 | 0.16 | 14.28% | 11.40% |
| Mar-26 · Q | 36.71 | 2.99 | 0.13 | 11.39% | 8.15% |
| FY25-26 | 119.86 | 16.13 | 0.67 | 18.08% | 13.46% |
Quarter on quarter
- Revenue, quarter on quarter
- -5.5%
- Net profit, quarter on quarter
- +32.4%
- Operating margin, quarter on quarter
- +289 bps
Disclosure profile 15 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 2 |
| Change in Management | 1 |
| Results | 1 |
| Selected sub-total | 4 |
| Procedural | |
| Newspaper Publication | 3 |
| AGM / EGM | 2 |
| Board Meeting | 2 |
| Annual Report | 1 |
| Book Closure | 1 |
| General | 1 |
| Trading Window | 1 |
| Procedural sub-total | 11 |
| Total | 15 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
15 filings · 4 selected · busiest 2026-08-14 and 2026-09-04
Filing rhythm · the twelve most recent
2026-08-142026-10-01
SelectedProcedural
Filings
15 in the window · 6 earlier on record
-
1 October 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time, please find enclosed herewith voting results of the 41st eAGM of the Company held on September ....
AGM/EGM / AGM View filing →
-
30 September 2026 ·
Change in Management
Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015, we would like to inform you that the Company has received approval of its members by Special ....
Company Update / Change in Management View filing →
-
30 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of 41st eAGM of the Company held on Wednesday, September 30, 2026 through ....
AGM/EGM / AGM View filing →
-
22 September 2026 ·
Closure of Trading Window
Notice is hereby given that in pursuance of SEBI (PIT) Regulations, 2015 and Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window ....
Insider Trading / SAST / Closure of Trading Window View filing →
-
9 September 2026 ·
Newspaper Publication
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication of AGM Notice and eVoting related instructions advertisement published in ....
Company Update / Newspaper Publication View filing →
-
8 September 2026 ·
Approval Of Additional Products From Drugs Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies Limited
We are pleased to inform that our subsidiary company, M/s Deccan Remedies Limited has received approval from the Drugs Control Administration, Government of Andhra Pradesh granting License ....
Company Update / General View filing →
-
8 September 2026 ·
Reg. 34 (1) Annual Report.
With reference to the subject matter, As per the Regulation 34 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submits 41st Annual Report of Gennex ....
Others / Reg. 34 (1) Annual Report View filing →
-
4 September 2026 ·
Intimation Of Book Closure For The Purpose Of 41St AGM Of Gennex Laboratories Limited
Pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from September 23, 2026 to September 30, 2026 ....
Corp. Action / Book Closure View filing →
-
4 September 2026 ·
Board Meeting Outcome for Meeting Held On September 04, 2026
1. Draft Directors'/ Board Report for the Financial Year March 31, 2026; 2. The 41st Annual General Meeting of the Company to be held on Wednesday, September 30, 2026 at 12:30 P.M. through ....
Board Meeting / Outcome of Board Meeting View filing →
-
27 August 2026 ·
Board Meeting Intimation for For Fixing Date, Time And Venue Of 41St AGM Of The Company
Gennex Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. To decide regarding ....
Board Meeting / Board Meeting View filing →
-
17 August 2026 ·
Newspaper Publication
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter ....
Company Update / Newspaper Publication View filing →
-
14 August 2026 ·
Un-Audited Financial Results For The Quarter Ended June 30, 2026
In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Unaudited Standalone and Consolidated Financial Statement for the Quarter ended ....
Result / Financial Results View filing →
-
14 August 2026 ·
Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30, 2026
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....
Board Meeting / Outcome of Board Meeting View filing →
-
30 July 2026 ·
Newspaper Publication
Pursuant to Regulation 47 of SEBI (LODR), Regulations, 2015, please find enclosed herewith Newspaper Publication regarding Meeting of the Board of Directors of the Company scheduled to ....
Company Update / Newspaper Publication View filing →
-
29 July 2026 ·
Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Gennex Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. The Unaudited Financial ....
Board Meeting / Board Meeting View filing →
RSS feed for Gennex Laboratories Ltd · the 50 most recent filings